Bachem Holding Past Earnings Performance
Past criteria checks 4/6
Bachem Holding has been growing earnings at an average annual rate of 16.6%, while the Life Sciences industry saw earnings growing at 18.5% annually. Revenues have been growing at an average rate of 14.5% per year. Bachem Holding's return on equity is 8.5%, and it has net margins of 19.4%.
Key information
16.6%
Earnings growth rate
14.7%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 14.5% |
| Return on equity | 8.5% |
| Net Margin | 19.4% |
| Next Earnings Update | 25 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bachem Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 577 | 112 | 37 | 11 |
| 30 Sep 23 | 557 | 105 | 38 | 11 |
| 30 Jun 23 | 537 | 99 | 39 | 11 |
| 31 Mar 23 | 534 | 100 | 38 | 9 |
| 31 Dec 22 | 532 | 101 | 38 | 7 |
| 30 Sep 22 | 515 | 99 | 37 | 6 |
| 30 Jun 22 | 499 | 98 | 36 | 4 |
| 31 Mar 22 | 501 | 106 | 35 | 4 |
| 31 Dec 21 | 503 | 115 | 35 | 4 |
| 30 Sep 21 | 484 | 107 | 33 | 4 |
| 30 Jun 21 | 464 | 98 | 32 | 3 |
| 31 Mar 21 | 433 | 88 | 31 | 3 |
| 31 Dec 20 | 402 | 78 | 30 | 3 |
| 30 Sep 20 | 379 | 72 | 30 | 3 |
| 30 Jun 20 | 356 | 67 | 31 | 2 |
| 31 Mar 20 | 335 | 60 | 30 | 2 |
| 31 Dec 19 | 314 | 54 | 29 | 2 |
| 30 Sep 19 | 310 | 52 | 29 | 2 |
| 30 Jun 19 | 306 | 51 | 28 | 2 |
| 31 Mar 19 | 294 | 49 | 28 | 2 |
| 31 Dec 18 | 283 | 47 | 28 | 2 |
| 30 Sep 18 | 268 | 45 | 29 | 1 |
| 30 Jun 18 | 253 | 42 | 29 | 1 |
| 31 Mar 18 | 257 | 42 | 31 | 1 |
| 31 Dec 17 | 262 | 42 | 32 | 2 |
| 30 Sep 17 | 252 | 41 | 32 | 2 |
| 30 Jun 17 | 242 | 40 | 32 | 2 |
| 31 Mar 17 | 239 | 41 | 32 | 2 |
| 31 Dec 16 | 236 | 41 | 32 | 2 |
| 30 Sep 16 | 229 | 39 | 32 | 2 |
| 30 Jun 16 | 222 | 36 | 32 | 2 |
| 31 Mar 16 | 216 | 34 | 31 | 2 |
| 31 Dec 15 | 209 | 32 | 31 | 2 |
| 30 Sep 15 | 203 | 31 | 30 | 2 |
| 30 Jun 15 | 197 | 29 | 29 | 2 |
| 31 Mar 15 | 190 | 29 | 28 | 2 |
| 31 Dec 14 | 184 | 29 | 28 | 2 |
| 30 Sep 14 | 180 | 27 | 28 | 2 |
| 30 Jun 14 | 176 | 26 | 28 | 2 |
| 31 Mar 14 | 173 | 25 | 28 | 2 |
| 31 Dec 13 | 171 | 24 | 29 | 2 |
| 30 Sep 13 | 167 | 21 | 28 | 2 |
| 30 Jun 13 | 163 | 19 | 27 | 2 |
Quality Earnings: 0QND has high quality earnings.
Growing Profit Margin: 0QND's current net profit margins (19.4%) are higher than last year (18.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0QND's earnings have grown by 16.6% per year over the past 5 years.
Accelerating Growth: 0QND's earnings growth over the past year (11.1%) is below its 5-year average (16.6% per year).
Earnings vs Industry: 0QND earnings growth over the past year (11.1%) exceeded the Life Sciences industry 6.5%.
Return on Equity
High ROE: 0QND's Return on Equity (8.5%) is considered low.